Observational study of advanced lung squamous cell carcinoma
A Non-interventional Study and Its Clinical Relevance With Advanced Lung Squamous Cell Carcinoma
This study is collecting information from patients with advanced lung squamous cell carcinoma to better understand how the disease progresses and its characteristics without changing their current treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 130 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hunan Province Tumor Hospital Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT05984017 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect epidemiological data on patients with advanced or metastatic lung squamous cell carcinoma. It will gather information without intervening in the current medical practices of the participants. Patients will be monitored for measurable lesions according to RECIST 1.1 standards, allowing for a comprehensive understanding of the disease's progression and characteristics. The study is designed to enhance knowledge about this specific cancer type through careful data collection.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with confirmed advanced or metastatic lung squamous cell carcinoma.
Not a fit: Patients who do not have measurable lesions or are under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the natural history and epidemiology of advanced lung squamous cell carcinoma, potentially guiding future treatment approaches.
How similar studies have performed: While this approach is observational and may not have direct treatment implications, similar studies have successfully contributed to understanding cancer epidemiology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must be ≥18 years. * Provision of fully informed consent prior to any study specific procedures. * Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology. * According to the RECIST 1.1 standard, the patient must have at least one measurable lesion. Exclusion Criteria: * None
Where this trial is running
Changsha, Hunan
- Yongchang Zhang — Changsha, Hunan, China (Recruiting)
Study contacts
- Principal investigator: Yongchang Zhang, MD — Hunan Cancer Hospital
- Study coordinator: Yongchang C Zhang, MD
- Email: zhangyongchang@csu.edu.cn
- Phone: +8613873123436
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.